"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”
A trial looking at chemotherapy for advanced melanoma of the skin or eye
This trial looked at gemcitabine (Gemzar) and treosulfan for melanoma that has spread (metastasized) and cannot be removed with an operation.
More about this trial
Advanced melanoma can be difficult to treat. Doctors can use chemotherapy but often it does not work very well. Treosulfan is usually used to treat other types of cancer. Gemcitabine and treosulfan together is a new and experimental combination of chemotherapy for advanced melanoma. Doctors wanted to see if it would work well for people with advanced melanoma.
The aims of the trial were to find out
- The best dose of gemcitabine to give
- More about the side effects
- How well this combination worked for advanced melanoma
Summary of results
The research team concluded that gemcitabine and treousulfan together could possibly be useful for treating people with a specific type of advanced melanoma called melanoma of the eye (uveal melanoma). But there were only 5 people with eye melanoma in the trial so it was difficult for the researchers to be sure.
The trial recruited 27 patients with advanced melanoma. 22 had melanoma of the skin and 5 had melanoma of the eye. The results showed
- The cancer did not go away completely (a ‘
complete response') in any patients
- The cancer did not slow or stop growing enough to be classified as a ‘
partial response’ to treatment in any of the patients
- In 2 people with melanoma of the eye, the cancer slowed or stopped growing a little (a ‘minor response’)
- In 13 people the cancer remained the same (‘
- In 12 people the cancer continued to grow
The most common side effects were a drop in the number of blood cells feeling or being sick, skin rash and constipation.
The finding that this treatment might be useful for melanoma of the eye is supported by the results of other, similar clinical trials.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr P Corrie
Addenbrooke's Charities Endowment Fund
Eli Lilly and Company Limited